for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

45.10USD

Change

0.22(+0.49%)

Volume

5,467,463

Today's Range

44.84

 - 

45.47

52 Week Range

33.53

 - 

46.85

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
44.88
Open
45.08
Volume
5,467,463
3M AVG Volume
87.20
Today's High
45.47
Today's Low
44.84
52 Week High
46.85
52 Week Low
33.53
Shares Out (MIL)
5,031.74
Market Cap (MIL)
112,046.20
Forward P/E
14.76
Dividend (Yield %)
4.90

Next Event

Q4 2021 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

India CCI OKs Acquisition Of Glaxosmithkline Asia Private

Glaxosmithkline Appoints Tony Wood As CSO Designate

23andMe Announces Extension Of GSK Collaboration And Update On Joint Immuno-Oncology Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Industry

Major Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Global Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

41.1K

2019

43.1K

2020

43.7K

2021(E)

46.4K
EPS (USD)

2018

3.104

2019

3.161

2020

2.973

2021(E)

3.060
Price To Earnings (TTM)
19.34
Price To Sales (TTM)
2.47
Price To Book (MRQ)
5.38
Price To Cash Flow (TTM)
11.70
Total Debt To Equity (MRQ)
165.99
LT Debt To Equity (MRQ)
134.42
Return on Investment (TTM)
9.78
Return on Equity (TTM)
6.27

Latest News

Latest News

GSK, Vir ramping up U.S. output of COVID antibody drug

GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.

Unilever neatly soaks up India’s two-tier recovery

(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)

UPDATE 2-Oil stocks, GSK weakness pull FTSE 100 lower; Deliveroo jumps

London's FTSE 100 slipped on Thursday on weakness in oil stocks and GlaxoSmithKline, while food delivery platform Deliveroo jumped on order growth hitting the top of its outlook range.

Unilever strategy under scrutiny after short-lived GSK skirmish

Unilever's strategy was under the investor microscope on Thursday after the consumer goods group effectively abandoned its 50 billion pound ($68 billion) pursuit of GlaxoSmithKline's consumer healthcare business.

Unilever will not raise rejected 50 billion pound bid for GSK consumer arm

Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.

FTSE 100 gains on mining strength, Unilever boost; Deliveroo jumps

London's FTSE 100 rose on Thursday led by mining stocks and Unilever after the consumer products maker dropped its plan to acquire GSK's healthcare business, while food delivery platform Deliveroo jumped on order growth hitting the top of its outlook range.

Unilever shares gain after opting not to lift bid for GSK assets

Shares in consumer goods giant Unilever inched roughly 2% higher on Thursday after it said late on Wednesday it would not raise its rejected 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare business.

GSK chief scientist Barron to leave for U.S. biotech start-up

GlaxoSmithKline said on Wednesday that Hal Barron will end his position as chief scientific officer in August after less than five years to run a new privately owned start-up biotech company.

Dove soap maker Unilever signals pursuit of GSK consumer arm; shares fall

Unilever signalled on Monday it would pursue a deal for GSK's consumer business, calling it a "strong strategic fit", but Unilever shares slid more than 8%, highlighting investors' doubts about its 50-billion-pound ($68.4 billion) offer.

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare?

Unilever’s health kick is risky prescription

Alan Jope can no longer be accused of sitting on his hands. The Unilever boss on Monday signalled he would persevere with the attempted acquisition of GlaxoSmithKline’s consumer healthcare unit. But his rejected 50 billion pound offer was already pricey. Jope risks upsetting...

GSK leads FTSE 100 higher after rejecting Unilever offer for consumer arm

London's FTSE 100 rose on Monday as healthcare firm GlaxoSmithKline led gains after rejecting a 50-billion-pound takeover offer for its consumer products arm from Unilever, while energy and mining stocks also provided support.

BRIEF-GSK And Pfizer Hold Out For 60 Bln Stg Bid For Consumer Health Unit - FT

* GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT

Unilever to weigh raising offer for GSK's consumer assets - Bloomberg

Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc's consumer products division, Bloomberg reported https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit...

Unilever to weigh raising offer for Glaxo Consumer unit - Bloomberg

Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc's consumer products division, Bloomberg reported https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit...

BRIEF-Unilever Has Held Talks With Banks About Additional Financing For Potential Sweetened Offer For GSK's Consumer Products Division - Bloomberg News

* UNILEVER HAS HELD TALKS WITH BANKS ABOUT ADDITIONAL FINANCING FOR POTENTIAL SWEETENED OFFER FOR GSK'S CONSUMER PRODUCTS DIVISION - BLOOMBERG NEWS Source text for Eikon: Further company coverage:

GSK rejects 50-billion-pound Unilever offer for consumer assets

GlaxoSmithKline on Saturday said it had rejected a 50-billion-pound offer from Unilever for its consumer goods arm, saying it "fundamentally undervalued" the business and its future prospects and that it would stick to its plan of spinning off the unit.

BRIEF-Arcellx Inc Files For IPO Of Up To $100 Million – SEC Filing

* ARCELLX INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING

Factbox-Front runners in development of antibody drugs against COVID-19

AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies, but the spread of the highly contagious Omicron variant has put the therapies'...

WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool

A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up